Stay updated on Phase 2 NSCLC Platform Study Post-Osimertinib Clinical Trial

Sign up to get notified when there's something new on the Phase 2 NSCLC Platform Study Post-Osimertinib Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Phase 2 NSCLC Platform Study Post-Osimertinib Clinical Trial page

  1. Check
    2 days ago
    No Change Detected
  2. Check
    9 days ago
    Change Detected
    Summary
    The site footer’s revision label changed from v3.7.2 to v3.8.0.
    Difference
    0.1%
    Check dated 2026-11-02T13:46:41.000Z thumbnail image
  3. Check
    16 days ago
    Change Detected
    Summary
    A banner announces NIH website transition updates and says federal agencies are using “Super Intelligence” in place of “Artificial Intelligence” during the transition.
    Difference
    0.4%
    Check dated 2026-10-26T15:16:17.000Z thumbnail image
  4. Check
    23 days ago
    Change Detected
    Summary
    The website footer revision label changed from v3.7.1 to v3.7.2.
    Difference
    0.1%
    Check dated 2026-10-19T14:44:22.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    The site footer’s release label changed from v3.7.0 to v3.7.1.
    Difference
    0.1%
    Check dated 2026-10-12T14:52:16.000Z thumbnail image
  6. Check
    51 days ago
    Change Detected
    Summary
    A new revision entry labeled v3.7.0 was added to the record history, and the previous revision v3.6.6 was removed.
    Difference
    0.1%
    Check dated 2026-09-21T22:13:21.000Z thumbnail image
  7. Check
    72 days ago
    Change Detected
    Summary
    The history now includes a new revision entry for v3.6.6, replacing the previous v3.6.5. This indicates an update to the study record's documentation rather than any substantive changes to the study data.
    Difference
    0.1%
    Check dated 2026-08-31T18:23:07.000Z thumbnail image

Stay in the know with updates to Phase 2 NSCLC Platform Study Post-Osimertinib Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Phase 2 NSCLC Platform Study Post-Osimertinib Clinical Trial page.